Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering of 2,875,000 shares of common stock of Adamas Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “ADMS.”
Based in Emeryville, California, Adamas Pharmaceuticals, Inc. is a biopharmaceutical company committed to developing product candidates for the treatment of chronic disorders of the central nervous system. Adamas Pharmaceuticals, Inc. seeks to achieve this by enhancing the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Emily Roberts and Stephanie Lai. The tax team included partner Rachel D. Kleinberg and associate Alexander Wu. The intellectual property and technology team included associate Michelle Gross. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.